This Biotech Skyrocketed 84% in 2 Days, But Is It Warranted?

1 min read

Clinical-trial data can drive the valuation of biotech companies higher, but investors need to be able to recognize how much of the valuation increase is justified by the data and how much might be driven by external forces like a short squeeze. IGM Biosciences (NASDAQ: IGMS) seems to have experienced the latter after releasing data at the American Society of Hematology Annual Meeting earlier this month.

In this video from Motley Fool Live, recorded on Dec. 14, Corinne Cardina, bureau chief of healthcare and cannabis, and Fool.com contributor Brian Orelli discuss what caused IGM’s apparently unwarranted increase.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

$900 Billion Coronavirus Deal, With Stimulus Checks, Likely to Pass Monday Morning

Next Story

Why Tesla Stock Fell Sharply on Monday

Latest from Blog